ovarian cancer
Showing NaN - NaN of 161
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)
Not yet recruiting
- Solid Tumor, Adult
- +19 more
- A2B694
- xT CDx with HLA-LOH Assay
-
Duarte, California
- +9 more
Sep 22, 2023
Ovarian Cancer Trial in Houston (Shared Medical Decision Tool, Engaging Patients in Decision Making, Literacy Spanish Language)
Recruiting
- Ovarian Cancer
- Shared Medical Decision Tool
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 7, 2023
Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma Trial in Houston (TROP2-CAR-NK, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Pancreatic Cancer
- +2 more
- TROP2-CAR-NK
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 27, 2023
Ovarian Cancer Trial in Houston (Hyperpolarized 13-C-pyruvate)
Not yet recruiting
- Ovarian Cancer
- Hyperpolarized 13-C-pyruvate
-
Houston, TexasM D Anderson Cancer Center
May 10, 2023
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer Trial in Houston (IDE-161)
Not yet recruiting
- Advanced or Metastatic Solid Tumors
- +4 more
-
Houston, TexasMD Anderson
Mar 27, 2023
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Houston (Paclitaxel, Carboplatin, Bevacizumab)
Recruiting
- Ovarian Cancer
- +2 more
- Paclitaxel
- +3 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 13, 2023
Ovarian Cancer Trial in Houston (Nivolumab, Etigilimab)
Not yet recruiting
- Ovarian Cancer
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified
Recruiting
- Endometrial Cancer
- +8 more
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
-
Orlando, Florida
- +21 more
Feb 2, 2023
Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)
Recruiting
- Minimal Residual Disease
- +11 more
- ELI-002 2P
-
Duarte, California
- +10 more
Jan 18, 2023
Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer Trial in Israel, United States (CM-24 and Nivolumab - Dose
Recruiting
- Solid Tumor
- +6 more
- CM-24 and Nivolumab - Dose Escalation
- +4 more
-
Scottsdale, Arizona
- +10 more
Jan 17, 2023
Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)
Recruiting
- Advanced Malignancies
- +4 more
- Avelumab
- +7 more
-
Fayetteville, Arkansas
- +61 more
Jan 10, 2023
NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)
Recruiting
- Non-small Cell Lung Cancer
- +11 more
-
Birmingham, Alabama
- +32 more
Jan 4, 2023
Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))
Completed
- Ovarian Cancer
- +7 more
- Enapotamab vedotin (HuMax-AXL-ADC)
-
Phoenix, Arizona
- +40 more
Dec 12, 2022
Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer Trial in Belgium, United Kingdom, United States
Completed
- Biliary Tract Cancer (BTC)
- +5 more
- INCB001158
- +6 more
-
Birmingham, Alabama
- +9 more
Dec 22, 2022
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)
Active, not recruiting
- Advanced Solid Malignancy
- +13 more
-
Los Angeles, California
- +33 more
Dec 22, 2022
NSCLC, Pancreatic Cancer, Colorectal Cancer Trial in Canada, United States (PF-06946860, Placebo for PF-06946860)
Completed
- Non-small Cell Lung Cancer
- +9 more
- PF-06946860
- Placebo for PF-06946860
-
Little Rock, Arkansas
- +32 more
Dec 12, 2022
Ovarian Cancer, Breast Cancer, Colorectal Cancer Trial in Houston (Genetic Testing and Counseling, Screening Form)
Recruiting
- Ovarian Cancer
- +2 more
- Genetic Testing and Counseling
- Screening Form
-
Houston, TexasM D Anderson Cancer Center
Dec 12, 2022
Ovarian Cancer, Fallopian Tube Cancer Trial in Houston (RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO,
Recruiting
- Ovarian Cancer
- Fallopian Tube Cancer
- RIsk-Reducing Salpingectomy (RRS)
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High Trial in United States
Recruiting
- Advanced or Metastatic Solid Tumors
- +11 more
-
Tucson, Arizona
- +11 more
Dec 2, 2022